Physician profile
David B Frumberg
NPI 1932491404
$287,540.28
in general payments reported to CMS, 2019-2025
8 companies · $27K in 2025
The $27K reported for 2025 was more than what 93% of Orthopaedic Surgery providers received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,999 · 2020: $19K · 2021: $78K · 2022: $18K · 2023: $57K · 2024: $87K · 2025: $27K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $136K · Travel and Lodging: $33K · Food and Beverage: $2,127.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $135,787.21 |
| Travel and Lodging | $33,121.45 |
| Food and Beverage | $2,127.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Orthofix Medical, INC. | $242,370.83 | 2019-2025 | Truelok, Fitbone, Miscellaneous |
| Ultragenyx Pharmaceutical INC. | $32,924.00 | 2020-2021 | |
| Orthopediatrics Corp. | $6,460.00 | 2020-2024 | |
| Kyowa Kirin, INC. | $4,225.40 | 2024-2025 | Crysvita |
| Medtronic USA, INC. | $1,082.34 | 2019-2020 | |
| Depuy Synthes Sales INC. | $262.92 | 2019-2025 | Na, Hammerlock |
| Nuvasive, INC. | $173.79 | 2019 | |
| Gramercy Extremity Orthopedics LLC | $41.00 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Frumberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.